Ree, Anne Hansen http://orcid.org/0000-0002-8264-3223
Šaltytė Benth, Jūratė
Hamre, Hanne M.
Kersten, Christian
Hofsli, Eva
Guren, Marianne G.
Sorbye, Halfdan
Johansen, Christin
Negård, Anne
Bjørnetrø, Tonje
Nilsen, Hilde L.
Berg, Jens P.
Flatmark, Kjersti
Meltzer, Sebastian http://orcid.org/0000-0001-6640-3927
Article History
Received: 14 December 2023
Revised: 12 April 2024
Accepted: 15 April 2024
First Online: 25 April 2024
Competing interests
: AHR reports receiving research support from Bristol-Myers Squibb (on behalf of Akershus University Hospital) and a personal honorarium from MSD. HMH reports receiving personal honoraria from Bayer and Roche and serving on advisory boards of AstraZeneca, Eisai and InCyte. CK reports serving on advisory boards of AstraZeneca and Roche. HS reports receiving personal honoraria from Ipsen, Pierre Fabre and SAM Nordic and serving on advisory boards of Bayer, Hutchison MediPharma, ITM and AAA Pharma. SM reports serving on advisory board of GSK. The remaining authors declare no competing interests.
: Protocol approval for the METIMMOX trial was obtained from the Regional Committee for Medical and Health Research Ethics of South-East Norway (2017/1850), the Norwegian Medical Agency (17/12752) and the institutional review boards. The trial was conducted in accordance with the guidelines of Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent.